NICE does not recommend Gazyvaro for CLL - Roche/Genentech

Gazyvaro (obinutuzumab) from Roche in combination with chlorambucil is not recommended by The National Institute for Health and Care Excellence (NICE) within its marketing authorisation, for adults with untreated Chronic Lymphocytic Leukaemia who have comorbidities that make full-dose fludarabine-based therapy unsuitable for them. People currently having treatment initiated within the NHS with obinutuzumab in combination with chlorambucil that is not recommended for them by NICE in the guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop. Although obinutuzumab is a clinically effective treatment, there were too many uncertainties in the company's submission and we cannot be confident that it is an effective use of NHS resources," said NICE's chief executive, Andrew Dillon.